{"datetime": "2020-03-03 12:09:56.580131", "filename": "2004285230", "mainterms": [{"score": 0.9976247549057007, "sentences": ["DCV, daclatasvir; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR12, sustained virologic response at 12 weeks post-treatment.    ", "ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    "], "term": "human", "termType": "MED", "weight": "b"}, {"score": 0.9967784881591797, "sentences": ["Although the number of observed virologic failures was small (7/420), when compared with those without virologic failure (413/420), those with failure were more often male (86% with failure [6/7] versus 68% without failure [280/413]), treatment experienced (57% [4/7] versus 38% [157/ 413]), or had baseline viral loads \u22656 million", "The DCV group had higher mean serum alanine aminotransferase, and a higher proportion of patients under 65, males, patients with cirrhosis, prior failures on IFN-free regimens containing SOF Page 4 of 15    *p-values are for overall non-DVC-based regimens versus DCV-based regimens."], "term": "male", "termType": "MED", "weight": "b"}, {"score": 0.9961174726486206, "term": "female", "termType": "MED", "weight": "b"}, {"score": 0.9865643978118896, "sentences": ["Patients and treatment : CMPASS-EU enrolled adults Patients were enrolled at 54 sites across the three countries (Belgium: 14; Germany: 34; the Netherlands: 6), and informed consent was obtained from all patients entering the study."], "term": "adult", "termType": "MED", "weight": "b"}, {"score": 0.9844496846199036, "sentences": ["A prospective, observational cohort study in Germany, Belgium and the Netherlands collected baseline data from all patients initiating a new HCV regimen, with 12-month follow-up of DCV-based treatments.", ": CMPASS-EU was a prospective, observational, multicenter, cohort study in three European countries (Germany, Belgium and the Netherlands), with both cross-sectional and longitudinal components (ClinicalTrials.gov Identifier: NCT02368522)."], "term": "prospective study", "termType": "MED", "weight": "b"}, {"score": 0.9679665565490723, "term": "major clinical study", "termType": "MED", "weight": "b"}, {"links": [{"sublinks": [{"sentences": ["Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a French early access Cohort."], "term": "liver disease"}, {"sentences": ["DCV, daclatasvir; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR12, sustained virologic response at 12 weeks post-treatment.    "], "term": "virus hepatitis"}, {"sentences": ["DCV, daclatasvir; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR12, sustained virologic response at 12 weeks post-treatment.    "], "term": "hepatitis C"}, {"sentences": ["Alloral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:"], "term": "virus infection"}, {"sentences": ["Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)."], "term": "hepatitis A"}, {"sentences": ["Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence."], "term": "hepatitis"}, {"sentences": ["Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence."], "term": "graft infection"}, {"sentences": ["Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence."], "term": "liver cirrhosis"}, {"sentences": ["Subjects: Gastroenterology; Hepatology; Infectious Diseases; ClinicalPharmacology & Therapeutics Keywords: hepatitis C; daclatasvir; sofosbuvir; ribavirin; real-world; quality-of-life; efficacy; safety; cirrhosis; HIV coinfection 2."], "term": "infectious hepatitis"}, {"sentences": ["Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic hepatitis C virus (HCV) infection and evaluate effectiveness, safety and quality-of-life (QoL) changes for DCV-based regimens."], "term": "chronic hepatitis C"}, {"sentences": ["Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic hepatitis C virus (HCV) infection and evaluate effectiveness, safety and quality-of-life (QoL) changes for DCV-based regimens."], "term": "chronic hepatitis"}, {"sentences": ["Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic hepatitis C virus (HCV) infection and evaluate effectiveness, safety and quality-of-life (QoL) changes for DCV-based regimens."], "term": "infection"}], "term": "adverse drug reaction - disease"}], "score": 0.9544870853424072, "sentences": ["Since the completion of this study, the original branded version of daclatasvir is no longer marketed in the European Union, but remains available in a number of other regions, including China, Australia, and Japan.", "Study objectives and assessments : The study had two primary objectives: to quantify the effectiveness of daclatasvir-containing regimens in real-life clinical care, as measured by SVR12, and to describe and compare the demographic and clinical characteristics of patients initiating a new HCV treatment regimen, identifying those characteristics associated with the initiation of DCV-containing, versus non-DCV, regimens.    ", "Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a French early access Cohort.", "DCV, daclatasvir; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR12, sustained virologic response at 12 weeks post-treatment.    ", "Cite this article as: Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries : The CMPASS-EU cohort study, Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier & Joerg Petersen, Cogent Medicine (2020), 7: 1727169. ", "Alloral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:", "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).", "ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    ", "Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence.", "Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.", "Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort.", "Daclatasvir plus sofosbuvir for HCV in patients coinfected with The New England Journal of Medicine, 373(8), 714\u2013725.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin, including patient-reported outcomes, in routine practice in three European countries: the CMPASS-EU cohort study.", "Subjects: Gastroenterology; Hepatology; Infectious Diseases; ClinicalPharmacology & Therapeutics Keywords: hepatitis C; daclatasvir; sofosbuvir; ribavirin; real-world; quality-of-life; efficacy; safety; cirrhosis; HIV coinfection 2.", "Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.", "Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic hepatitis C virus (HCV) infection and evaluate effectiveness, safety and quality-of-life (QoL) changes for DCV-based regimens.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study", "Additionally, generic daclatasvir is now widely used in many lower and middle income countries worldwide via the Medicines Patent Pool, as the DCV+SOF combination remains an integral part of World Health Organization Treatment Guidelines (World Health Organization, 2018a; World Health Organization, 2018b; Simmons, Cooke, & Miraldo, 2019).", "Hepatitis C may be cured by a course of antiviral drugs, such as the combination of daclatasvir (DCV) and sofosbuvir (SOF) with or without ribavirin (RBV).", "Thus it is anticipated that observational data from our study, accruing as they do from realworld clinical experience, will be of value beyond the geography of their origin and prove of interest to physicians where daclatasvir treatment remains a therapeutic option.  "], "term": "daclatasvir", "termType": "DRG", "weight": "a"}, {"links": [{"sublinks": [{"sentences": ["Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a French early access Cohort."], "term": "liver disease"}, {"sentences": ["Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort."], "term": "hepatitis"}, {"sentences": ["Cite this article as: Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries : The CMPASS-EU cohort study, Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier & Joerg Petersen, Cogent Medicine (2020), 7: 1727169."], "term": "hepatitis C"}, {"sentences": ["Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)."], "term": "hepatitis A"}, {"sentences": ["Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)."], "term": "virus hepatitis"}, {"sentences": ["Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)."], "term": "virus infection"}, {"sentences": ["Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence."], "term": "graft infection"}, {"sentences": ["Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence."], "term": "liver cirrhosis"}, {"sentences": ["Subjects: Gastroenterology; Hepatology; Infectious Diseases; ClinicalPharmacology & Therapeutics Keywords: hepatitis C; daclatasvir; sofosbuvir; ribavirin; real-world; quality-of-life; efficacy; safety; cirrhosis; HIV coinfection 2."], "term": "infectious hepatitis"}, {"sentences": ["Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials."], "term": "infection"}], "term": "adverse drug reaction - disease"}], "score": 0.953571617603302, "sentences": ["\u00b1 ribavirin [RBV]) and 444 non-DCV regimens.", "Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a French early access Cohort.", "Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort.", "Cite this article as: Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries : The CMPASS-EU cohort study, Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier & Joerg Petersen, Cogent Medicine (2020), 7: 1727169. ", "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).", "Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.", "Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin, including patient-reported outcomes, in routine practice in three European countries: the CMPASS-EU cohort study.", "Subjects: Gastroenterology; Hepatology; Infectious Diseases; ClinicalPharmacology & Therapeutics Keywords: hepatitis C; daclatasvir; sofosbuvir; ribavirin; real-world; quality-of-life; efficacy; safety; cirrhosis; HIV coinfection 2.", "Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study", "Hepatitis C may be cured by a course of antiviral drugs, such as the combination of daclatasvir (DCV) and sofosbuvir (SOF) with or without ribavirin (RBV).", "Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials."], "term": "ribavirin", "termType": "DRG", "weight": "a"}, {"links": [{"sublinks": [{"sentences": ["Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a French early access Cohort."], "term": "liver disease"}, {"sentences": ["Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort."], "term": "hepatitis"}, {"sentences": ["Cite this article as: Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries : The CMPASS-EU cohort study, Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier & Joerg Petersen, Cogent Medicine (2020), 7: 1727169."], "term": "hepatitis C"}, {"sentences": ["Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials."], "term": "chronic hepatitis C"}, {"sentences": ["Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials."], "term": "virus hepatitis"}, {"sentences": ["Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials."], "term": "virus infection"}, {"sentences": ["Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials."], "term": "chronic hepatitis"}, {"sentences": ["Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials."], "term": "infection"}, {"sentences": ["Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)."], "term": "hepatitis A"}, {"sentences": ["Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence."], "term": "graft infection"}, {"sentences": ["Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence."], "term": "liver cirrhosis"}, {"sentences": ["Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial."], "term": "hepatitis B"}, {"sentences": ["Subjects: Gastroenterology; Hepatology; Infectious Diseases; ClinicalPharmacology & Therapeutics Keywords: hepatitis C; daclatasvir; sofosbuvir; ribavirin; real-world; quality-of-life; efficacy; safety; cirrhosis; HIV coinfection 2."], "term": "infectious hepatitis"}], "term": "adverse drug reaction - disease"}], "score": 0.9457154273986816, "sentences": ["Finally, in Germany, there were no restrictions on fibrosis, but reimbursement decisions are largely driven by cost, and many non-GT-3 patients will have been prescribed (or switched to) the fixed-dose coformulation of ledipasvir and sofosbuvir following its EMA registration in December 2014, shortly after the registration of DCV.  ", "Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a French early access Cohort.", "Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort.", "Cite this article as: Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries : The CMPASS-EU cohort study, Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier & Joerg Petersen, Cogent Medicine (2020), 7: 1727169. ", "Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials.", "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).", "Alloral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:", "Reviewing editor: Udo Schumacher, University Medical Center Hamburg- Eppendorf, Hamburg, Germany Additional information is available at the end of the article Page 1 of 15 (469 with sofosbuvir [SOF] Patients and methods :  2.1.", "ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    ", "Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence.", "Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.", "Daclatasvir plus sofosbuvir for HCV in patients coinfected with The New England Journal of Medicine, 373(8), 714\u2013725.", "Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin, including patient-reported outcomes, in routine practice in three European countries: the CMPASS-EU cohort study.", "Subjects: Gastroenterology; Hepatology; Infectious Diseases; ClinicalPharmacology & Therapeutics Keywords: hepatitis C; daclatasvir; sofosbuvir; ribavirin; real-world; quality-of-life; efficacy; safety; cirrhosis; HIV coinfection 2.", "Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study", "Hepatitis C may be cured by a course of antiviral drugs, such as the combination of daclatasvir (DCV) and sofosbuvir (SOF) with or without ribavirin (RBV).", "Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials."], "term": "sofosbuvir", "termType": "DRG", "weight": "a"}, {"score": 0.941278338432312, "sentences": ["There were five deaths during the study, representing 1% of the follow-up cohort.", "Cite this article as: Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries : The CMPASS-EU cohort study, Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier & Joerg Petersen, Cogent Medicine (2020), 7: 1727169. ", "A prospective, observational cohort study in Germany, Belgium and the Netherlands collected baseline data from all patients initiating a new HCV regimen, with 12-month follow-up of DCV-based treatments.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin, including patient-reported outcomes, in routine practice in three European countries: the CMPASS-EU cohort study.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study", ": CMPASS-EU was a prospective, observational, multicenter, cohort study in three European countries (Germany, Belgium and the Netherlands), with both cross-sectional and longitudinal components (ClinicalTrials.gov Identifier: NCT02368522)."], "term": "cohort analysis", "termType": "MED", "weight": "a"}, {"score": 0.9350458979606628, "sentences": ["In addition to virologic efficacy, treatment was associated with statistically significant improvements in health-related QoL measures over a period of 1 year on- and off-treatment, particularly in patients with cirrhosis.", "In summary, these results confirm the effectiveness and tolerability of DCV+SOF\u00b1RBV for the treatment of HCV in the real-world setting, including subgroups of patients with cirrhosis, HCV/ HIV co-infection, and illicit drug use or OST.", "Baseline demographic and disease characteristics : \u2020Percentage is of patients with cirrhosis;", "The pattern of changes from baseline in these four PROs for those with versus without cirrhosis (Supplementary Figure 2) was therefore similar to that observed according to RBV use (Figure 2).    ", ": Table 2 shows DCV initiation by cirrhosis status and HCV GT.", "GT-3-infected patients with cirrhosis received more intensive treatment over a longer period than those without.", "Subjects: Gastroenterology; Hepatology; Infectious Diseases; ClinicalPharmacology & Therapeutics Keywords: hepatitis C; daclatasvir; sofosbuvir; ribavirin; real-world; quality-of-life; efficacy; safety; cirrhosis; HIV coinfection 2.", "In addition to the treatment imbalances associated with cirrhosis, patients without cirrhosis were mostly treated for 12 weeks but were more likely to have received RBV for this time if they were GT-1 infected; 28% of all GT-1a non-cirrhotic patients and 33% of GT-1b, versus 6% of GT-3, received DCV+SOF +RBV for 12 weeks.", "By contrast, 92% of GT-3 patients without cirrhosis (216/234) received DCV+SOF without RBV, and nearly all of them (93%; 201/216) were treated for 12 weeks.", "These results contrast with GT-1 infection, where RBV use was similarly associated with cirrhosis but most patients (81% GT-1a; 70% GT-1b) received 12 weeks of treatment irrespective of cirrhosis status.", "The majority of patients without cirrhosis received DCV+SOF for 12 weeks without RBV irrespective of GT, while the majority of those with cirrhosis received DCV+SOF with RBV for 12 weeks (GT-1) or 24 weeks (GT-3).", "Sustained virologic response on DCV+SOF\u00b1RBV (observed) was 96\u2013100% across subgroups of IDU, HIV co-infection, HCV genotype and cirrhosis status.", "Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence.", "; \u00a7 BMI 17/21; cirrhosis stage (comp. or decomp.) 0/1; FIB-4 44/34; HIV/HCV co-infected 48/45; HCV RNA 15/21; Treatment experience 4/2; ALT 8/11; platelets 11/16; hemoglobin 11/17; abnormal creatinine 39/48; alcohol use 85/54.", "Overall, observed SVR12 was 99% in the primary analysis irrespective of cirrhosis; in sensitivity analysis 1, 95% of patients with Page 11 of 15 cirrhosis and 98% without achieved SVR12, while in sensitivity analysis 2, SVR12 rates were 90% with and 91% without cirrhosis.", "1 (death/discontinuation due to AE = failure) in patients with cirrhosis were 100% (17/17) for GT-1a infection, 98% (40/41) for GT-1b, and 95% (80/84) for GT-3, whereas for sensitivity analysis 2 Patient-reported outcomes : MMRM-estimated changes from baseline in EQ-5D total score, EQ-VAS and SF-36 global physical and mental health scores over time for patients receiving DCV+SOF, according to concomitant RBV use, are shown in Figure 2.", "Very high rates (\u226596%) of post-treatment sustained virologic response were seen in the primary analysis, irrespective of liver cirrhosis, coinfection with HIV, or illicit drug use.", "Multivariate predictors of DCV treatment included genotype 3 infection (odds ratio 85.9 [95% confidence interval 43.5\u2013170]), age \u226565 years (2.0 [1.2\u20133.3]), and cirrhosis (3.3 [2.0\u20135.3]).", "Despite this treatment difference, SVR12 rates in GT3-infected patients were very similar with or without cirrhosis.", "DCV initiation by cirrhosis status and HCV genotype, 3.4.", "DCV initiation by cirrhosis status and HCV genotype", "Among patients with cirrhosis, observed SVR12 was 100% in both GT-1a (17/17) and GT-1b infection (40/40), and 99% (80/81) for GT-3.", "Factors associated with initiation of DCV-based regimens : The largest independent predictor of DCV use in this study was GT-3 infection, and older age (65 years or over), cirrhosis/fibrosis, and clinically significant abnormalities in platelet levels were also predictive.", "The majority of patients with cirrhosis who received DCV-based regimens also received RBV (Table 2).", "The DCV group had higher mean serum alanine aminotransferase, and a higher proportion of patients under 65, males, patients with cirrhosis, prior failures on IFN-free regimens containing SOF Page 4 of 15    *p-values are for overall non-DVC-based regimens versus DCV-based regimens.", "These rates are slightly higher than GT-3 data for DCV+SOF\u00b1RBV in cirrhosis from the French ATU compassionate-use program (Hezode et al., 2017), consistent with the less clinically advanced nature of the CMPASS-EU patient group.  "], "term": "liver cirrhosis", "termType": "DIS", "weight": "b"}, {"score": 0.9145320057868958, "sentences": ["A prospective, observational cohort study in Germany, Belgium and the Netherlands collected baseline data from all patients initiating a new HCV regimen, with 12-month follow-up of DCV-based treatments.", ": CMPASS-EU was a prospective, observational, multicenter, cohort study in three European countries (Germany, Belgium and the Netherlands), with both cross-sectional and longitudinal components (ClinicalTrials.gov Identifier: NCT02368522).", "Thus it is anticipated that observational data from our study, accruing as they do from realworld clinical experience, will be of value beyond the geography of their origin and prove of interest to physicians where daclatasvir treatment remains a therapeutic option.  "], "term": "observational study", "termType": "MED", "weight": "b"}, {"score": 0.8994854092597961, "sentences": ["For GT-3 infection, the mean age was 47.3 years, with 5% aged 65 or over; for GT-1b infection, the mean age was 65.6 years, with 50% aged 65 or over.", "Notably, the mean age of all patients in the study with severe hypertension (59.7 years) was significantly higher than those without it (50.6 years; p < 0.001), and significantly more of these hypertensive patients were aged \u226565 years (39% versus 12%; p < 0.001).    "], "term": "aged", "termType": "MED", "weight": "b"}, {"score": 0.891960859298706, "sentences": ["Cite this article as: Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries : The CMPASS-EU cohort study, Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier & Joerg Petersen, Cogent Medicine (2020), 7: 1727169. ", "In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir.", "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).", "Subjects: Gastroenterology; Hepatology; Infectious Diseases; ClinicalPharmacology & Therapeutics Keywords: hepatitis C; daclatasvir; sofosbuvir; ribavirin; real-world; quality-of-life; efficacy; safety; cirrhosis; HIV coinfection 2.", "The group have authored this manuscript on behalf of the many investigators who carried out this study of real-world hepatitis C treatment in Germany, Belgium and the Netherlands.    ", "In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study", "Hepatitis C may be cured by a course of antiviral drugs, such as the combination of daclatasvir (DCV) and sofosbuvir (SOF) with or without ribavirin (RBV).", "Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial.", "Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.", "Effect of voluntary licenses for hepatitis C medicines on access to treatment: A difference-in-differences analysis.", "    : ABOUT THE AUTHOR PUBLIC INTEREST STATEMENT Hepatitis C is a chronic, debilitating liver infection estimated by the WHO to kill almost 400,000 people annually.", "DCV, daclatasvir; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR12, sustained virologic response at 12 weeks post-treatment.    ", "Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy:", "Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence.", "These data represent real-world outcomes relevant to clinicians and patients where DCV and SOF are therapeutic options for hepatitis C. \u00a9 2020 The Author(s).", "Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic hepatitis C virus (HCV) infection and evaluate effectiveness, safety and quality-of-life (QoL) changes for DCV-based regimens.", "Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.", "A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.", "Virologic response among hepatitis C (HCV) patients treated in clinical practice [abstract 1084]. Hepatology, 54, 875A. Page 14 of 15 \u00a92020 The Author(s).", "In this paper, the antiviral efficacy and quality-of-life benefits of DCV+SOF(\u00b1RBV) treatment for hepatitis C were assessed in observational data reflecting its routine use in three European countries.", "Progress report on access to hepatitis C treatment:", "Management of hepatitis C virus infection.", "Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials.", "Alloral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:", "ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    ", "Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence.", "JAIDS Journal of Acquired Immune Deficiency Syndromes, 75(1), 97\u2013107. doi:10.1097/ Hepatitis C virus infection."], "term": "hepatitis C", "termType": "DIS", "weight": "a"}, {"score": 0.8576371669769287, "sentences": ["Cross-sectional baseline data were collected at time of initiation of any new HCV regimen, with longitudinal follow-up at 3, 6, only those patients prescribed a DCV-containing regimen.    ", "DCV initiation by cirrhosis status and HCV genotype, 3.4.", "Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials.", "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).", "Alloral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:", "In this study of real-world prescription and outcomes, HCV-infected patients initiating DCV+SOF \u00b1RBV were younger, GT-3 infected, and have more clinically advanced liver disease than those initiating other regimens.", "However, in Belgium, reimbursement for any direct-acting HCV antiviral was restricted to those with F3 or F4 liver fibrosis and liver transplant patients, and only DCV and SOF were reimbursed for GT-3 infection.", "Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials.", "Page 5 of 15 or HCV protease inhibitor, patients infected with GT-3, patients with a current or prior history of alcohol use, and illicit drug users (IDUs; defined as being on opioid substitution therapy [OST] or a current user of injection drugs).", "Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.", "SVR12 was achieved in 98% (413/ 420) overall, 100% (53/53) for HCV GT-1b, and 99% (281/285) for GT-3."], "term": "Hepatitis C virus genotype 3", "termType": "MED", "weight": "b"}, {"score": 0.855750322341919, "sentences": ["Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6:", "Leroy et al., 2016; Nelson et al., 2015) compared with the lesser GT-3 activity of the ledipasvir-, dasabuvir- and simeprevir-containing regimens that comprised almost 90% of the non-DCV group (Cheng et al., 2016; Kati et al., 2015; Moreno et al.", "A single patient initiated DCV+SOF+RBV with simeprevir.    "], "term": "simeprevir", "termType": "DRG", "weight": "b"}, {"links": [{"sublinks": [{"sentences": ["In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor."], "term": "hepatitis A"}, {"sentences": ["In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor."], "term": "virus hepatitis"}, {"sentences": ["In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor."], "term": "hepatitis C"}], "term": "adverse drug reaction - disease"}], "score": 0.8195953965187073, "sentences": ["Dasabuvir, ombitasvir and ritonavir-boosted paritaprevir (with or without RBV) accounted for a further 22\u201224% in each group, and SOF+RBV for 6\u20127%.", "In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor."], "term": "dasabuvir", "termType": "DRG", "weight": "b"}, {"score": 0.8124164342880249, "sentences": ["Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort.", "Very high rates (\u226596%) of post-treatment sustained virologic response were seen in the primary analysis, irrespective of liver cirrhosis, coinfection with HIV, or illicit drug use.", "DCV, daclatasvir; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR12, sustained virologic response at 12 weeks post-treatment.    ", "Sustained virologic response on DCV+SOF\u00b1RBV (observed) was 96\u2013100% across subgroups of IDU, HIV co-infection, HCV genotype and cirrhosis status."], "term": "sustained virologic response", "termType": "MED", "weight": "b"}, {"score": 0.758360743522644, "sentences": ["Dasabuvir, ombitasvir and ritonavir-boosted paritaprevir (with or without RBV) accounted for a further 22\u201224% in each group, and SOF+RBV for 6\u20127%."], "term": "ombitasvir", "termType": "DRG", "weight": "b"}, {"score": 0.755988597869873, "term": "middle aged", "termType": "MED", "weight": "b"}, {"score": 0.7306551337242126, "sentences": ["Furthermore, significant improvements in patient-reported quality-of-life were reported across patient subgroups.", "Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic hepatitis C virus (HCV) infection and evaluate effectiveness, safety and quality-of-life (QoL) changes for DCV-based regimens.", "Subjects: Gastroenterology; Hepatology; Infectious Diseases; ClinicalPharmacology & Therapeutics Keywords: hepatitis C; daclatasvir; sofosbuvir; ribavirin; real-world; quality-of-life; efficacy; safety; cirrhosis; HIV coinfection 2.", "In this paper, the antiviral efficacy and quality-of-life benefits of DCV+SOF(\u00b1RBV) treatment for hepatitis C were assessed in observational data reflecting its routine use in three European countries."], "term": "quality of life", "termType": "MED", "weight": "b"}, {"score": 0.727807343006134, "sentences": ["Dasabuvir, ombitasvir and ritonavir-boosted paritaprevir (with or without RBV) accounted for a further 22\u201224% in each group, and SOF+RBV for 6\u20127%."], "term": "paritaprevir", "termType": "DRG", "weight": "b"}, {"links": [{"sublinks": [{"sentences": ["In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir."], "term": "virus hepatitis"}, {"sentences": ["In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir."], "term": "hepatitis C"}, {"sentences": ["Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials."], "term": "infection"}], "term": "adverse drug reaction - disease"}], "score": 0.721372663974762, "sentences": ["Finally, in Germany, there were no restrictions on fibrosis, but reimbursement decisions are largely driven by cost, and many non-GT-3 patients will have been prescribed (or switched to) the fixed-dose coformulation of ledipasvir and sofosbuvir following its EMA registration in December 2014, shortly after the registration of DCV.  ", "(Dore et al., 2016), as well as with subanalyses of OST patients receiving velpatasvir + SOF in the phase III ASTRAL trials (SVR12 96%; n = 51) (Grebely et al., 2016a) or ledipasvir and SOF in the phase", "For both normotensive and hypertensive patients, the most common non-DCV combination was ledipasvir + SOF (with or without RBV), which accounted for 61\u201262% of non-DCV prescriptions.", "In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir.", "Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials."], "term": "ledipasvir", "termType": "DRG", "weight": "b"}, {"score": 0.7007348537445068, "sentences": ["Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic hepatitis C virus (HCV) infection and evaluate effectiveness, safety and quality-of-life (QoL) changes for DCV-based regimens.", "    : ABOUT THE AUTHOR PUBLIC INTEREST STATEMENT Hepatitis C is a chronic, debilitating liver infection estimated by the WHO to kill almost 400,000 people annually.", "Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials.", "Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection."], "term": "chronic hepatitis C", "termType": "DIS", "weight": "b"}, {"score": 0.6976510286331177, "sentences": ["Cross-sectional baseline data were collected at time of initiation of any new HCV regimen, with longitudinal follow-up at 3, 6, only those patients prescribed a DCV-containing regimen.    ", "Numerically, the high SVR12 rates reported from this present study, particularly for the sensitivity analyses which imputed treatment failures not directly observed in follow-up, are consistent with data from other real-world studies whose primary analyses were based on imputed failure (Hezode et al., 2017; Lacombe et al., 2017; Rockstroh et al., 2017; Welzel et al., 2016).", "There were five deaths during the study, representing 1% of the follow-up cohort.", "Page 9 of 15 The most frequent AEs (\u22655%) reported during the follow-up period were fatigue (9%) and headache (8%).", "A prospective, observational cohort study in Germany, Belgium and the Netherlands collected baseline data from all patients initiating a new HCV regimen, with 12-month follow-up of DCV-based treatments.", "A summary of the AEs reported during the follow-up period is presented in Supplementary Table 2."], "term": "follow up", "termType": "MED", "weight": "b"}, {"score": 0.6838123798370361, "sentences": [": CMPASS-EU was a prospective, observational, multicenter, cohort study in three European countries (Germany, Belgium and the Netherlands), with both cross-sectional and longitudinal components (ClinicalTrials.gov Identifier: NCT02368522).", "Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial."], "term": "multicenter study", "termType": "MED", "weight": "b"}, {"score": 0.6828616857528687, "sentences": ["A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.", "In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.", "DCV, daclatasvir; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR12, sustained virologic response at 12 weeks post-treatment.    ", "Management of hepatitis C virus infection.", "Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials.", "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).", "ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    ", "Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy:", "JAIDS Journal of Acquired Immune Deficiency Syndromes, 75(1), 97\u2013107. doi:10.1097/ Hepatitis C virus infection.", "Alloral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:", "Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence.", "Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.", "Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence.", "Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic hepatitis C virus (HCV) infection and evaluate effectiveness, safety and quality-of-life (QoL) changes for DCV-based regimens.", "Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.", "In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir.", "Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial."], "term": "Hepatitis C virus", "termType": "MED", "weight": "b"}, {"links": [{"sublinks": [{"term": "alcohol liver cirrhosis"}], "term": "drug therapy"}, {"term": "endogenous compound"}], "score": 0.6792365908622742, "sentences": ["; \u00a7 BMI 17/21; cirrhosis stage (comp. or decomp.) 0/1; FIB-4 44/34; HIV/HCV co-infected 48/45; HCV RNA 15/21; Treatment experience 4/2; ALT 8/11; platelets 11/16; hemoglobin 11/17; abnormal creatinine 39/48; alcohol use 85/54."], "term": "hemoglobin", "termType": "DRG", "weight": "b"}, {"score": 0.6019643545150757, "sentences": ["This lack of improvement in mental health among IDU patients likely reflects situational differences from the non-IDU group.", "Baseline predictors of prescription, longitudinal efficacy, and patientreported QoL outcomes (EQ-5D, EQ-VAS and SF-36 global physical/mental health) on DCV were assessed.", "There were no significant changes in either the SF-36 emotional role or mental health scales in the IDU group, and early improvements in the social functioning scale subsequently returned to baseline bymonth 12.", "It is notable that, in contrast to patients who had not used illicit drugs, no statistically significant improvement in SF-36 social or mental outcomes were observed in the IDU group, despite generally similar improvements in physical health outcomes.", "1 (death/discontinuation due to AE = failure) in patients with cirrhosis were 100% (17/17) for GT-1a infection, 98% (40/41) for GT-1b, and 95% (80/84) for GT-3, whereas for sensitivity analysis 2 Patient-reported outcomes : MMRM-estimated changes from baseline in EQ-5D total score, EQ-VAS and SF-36 global physical and mental health scores over time for patients receiving DCV+SOF, according to concomitant RBV use, are shown in Figure 2."], "term": "mental health", "termType": "MED", "weight": "b"}, {"score": 0.596015214920044, "sentences": ["There is a relative paucity of data on the efficacy of HCV regimens in active or recent drug users, given their exclusion from many randomized efficacy trials.", "In summary, these results confirm the effectiveness and tolerability of DCV+SOF\u00b1RBV for the treatment of HCV in the real-world setting, including subgroups of patients with cirrhosis, HCV/ HIV co-infection, and illicit drug use or OST."], "term": "drug efficacy", "termType": "MED", "weight": "b"}, {"links": [{"sublinks": [{"term": "infection"}], "term": "drug therapy"}], "score": 0.5822993516921997, "sentences": ["Finally, in Germany, there were no restrictions on fibrosis, but reimbursement decisions are largely driven by cost, and many non-GT-3 patients will have been prescribed (or switched to) the fixed-dose coformulation of ledipasvir and sofosbuvir following its EMA registration in December 2014, shortly after the registration of DCV.  ", "Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials."], "term": "ledipasvir plus sofosbuvir", "termType": "DRG", "weight": "b"}, {"score": 0.5769714117050171, "sentences": ["Of these, 1% (4/296) and 11% (19/ 174), respectively, were related to anemia.    "], "term": "anemia", "termType": "DIS", "weight": "b"}, {"score": 0.5749986171722412, "sentences": ["; \u00a7 BMI 17/21; cirrhosis stage (comp. or decomp.) 0/1; FIB-4 44/34; HIV/HCV co-infected 48/45; HCV RNA 15/21; Treatment experience 4/2; ALT 8/11; platelets 11/16; hemoglobin 11/17; abnormal creatinine 39/48; alcohol use 85/54.", "JAIDS Journal of Acquired Immune Deficiency Syndromes, 75(1), 97\u2013107. doi:10.1097/ Hepatitis C virus infection.", "Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials."], "term": "Hepatitis C virus genotype 1", "termType": "MED", "weight": "b"}, {"score": 0.5579140782356262, "sentences": ["Baseline predictors of prescription, longitudinal efficacy, and patientreported QoL outcomes (EQ-5D, EQ-VAS and SF-36 global physical/mental health) on DCV were assessed.", "Cite this article as: Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries : The CMPASS-EU cohort study, Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier & Joerg Petersen, Cogent Medicine (2020), 7: 1727169. ", "In this study of real-world prescription and outcomes, HCV-infected patients initiating DCV+SOF \u00b1RBV were younger, GT-3 infected, and have more clinically advanced liver disease than those initiating other regimens.", "Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic hepatitis C virus (HCV) infection and evaluate effectiveness, safety and quality-of-life (QoL) changes for DCV-based regimens.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin, including patient-reported outcomes, in routine practice in three European countries: the CMPASS-EU cohort study.", "For both normotensive and hypertensive patients, the most common non-DCV combination was ledipasvir + SOF (with or without RBV), which accounted for 61\u201262% of non-DCV prescriptions.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study", "In part, these differences reflect a combination of preferential DCV prescription to GT-3-infected patients\u2014due to its known high clinical activity against GT-3 (Hezode et al., 2017;"], "term": "prescription", "termType": "MED", "weight": "a"}, {"links": [{"sublinks": [{"sentences": ["ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    "], "term": "virus hepatitis"}, {"sentences": ["ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    "], "term": "hepatitis C"}], "term": "adverse drug reaction - disease"}, {"term": "endogenous compound"}], "score": 0.5370270013809204, "sentences": ["The DCV group had higher mean serum alanine aminotransferase, and a higher proportion of patients under 65, males, patients with cirrhosis, prior failures on IFN-free regimens containing SOF Page 4 of 15    *p-values are for overall non-DVC-based regimens versus DCV-based regimens.", "ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    "], "term": "alanine aminotransferase", "termType": "DRG", "weight": "b"}, {"score": 0.5288398265838623, "sentences": ["The study enrolled newly initiated patients to avoid selection bias, maximize the completeness of baseline data collection and allow assessment of ontreatment QoL changes via patient-reported outcome (PRO) instruments.", "Changes from baseline in patient-reported outcome measures were estimated using a mixed model for repeated measurements (MMRM) on non-transformed data, with baseline value and visit as fixed covariates."], "term": "patient-reported outcome", "termType": "MED", "weight": "b"}, {"score": 0.5273435711860657, "sentences": ["Significant improvements in EQ-5D, EQ-VAS and SF-36 outcome measures were typically observable by month 3 among those receiving DCV+SOF without RBV.", "IDU patients had statistically significant improvements in the EQ-5D total, EQ-VAS and SF-36 global physical health scores at most time points that were broadly comparable to those for nonIDU patients.", "Baseline predictors of prescription, longitudinal efficacy, and patientreported QoL outcomes (EQ-5D, EQ-VAS and SF-36 global physical/mental health) on DCV were assessed.", "There were no significant changes in either the SF-36 emotional role or mental health scales in the IDU group, and early improvements in the social functioning scale subsequently returned to baseline bymonth 12.", "Patients completed the EuroQol 5D (EQ-5D) survey of generic health status, including the EQ Visual Analog Scale (EQ-VAS), and also completed the Short-Form 36 (SF-36) instrument at baseline and at months 3, 6, 9 and 12.    ", "It is notable that, in contrast to patients who had not used illicit drugs, no statistically significant improvement in SF-36 social or mental outcomes were observed in the IDU group, despite generally similar improvements in physical health outcomes.", "1 (death/discontinuation due to AE = failure) in patients with cirrhosis were 100% (17/17) for GT-1a infection, 98% (40/41) for GT-1b, and 95% (80/84) for GT-3, whereas for sensitivity analysis 2 Patient-reported outcomes : MMRM-estimated changes from baseline in EQ-5D total score, EQ-VAS and SF-36 global physical and mental health scores over time for patients receiving DCV+SOF, according to concomitant RBV use, are shown in Figure 2."], "term": "Short Form 36", "termType": "MED", "weight": "b"}, {"score": 0.5175931453704834, "sentences": ["The study enrolled newly initiated patients to avoid selection bias, maximize the completeness of baseline data collection and allow assessment of ontreatment QoL changes via patient-reported outcome (PRO) instruments."], "term": "outcome assessment", "termType": "MED", "weight": "b"}, {"score": 0.49894586205482483, "sentences": ["Fatigue and headache were the most frequent AEs (\u22655% of patients).", "Page 9 of 15 The most frequent AEs (\u22655%) reported during the follow-up period were fatigue (9%) and headache (8%)."], "term": "fatigue", "termType": "DIS", "weight": "b"}, {"score": 0.4985005259513855, "sentences": ["SVR12 rates by sensitivity analysis", "1 (death/discontinuation due to AE = failure) in patients with cirrhosis were 100% (17/17) for GT-1a infection, 98% (40/41) for GT-1b, and 95% (80/84) for GT-3, whereas for sensitivity analysis 2 Patient-reported outcomes : MMRM-estimated changes from baseline in EQ-5D total score, EQ-VAS and SF-36 global physical and mental health scores over time for patients receiving DCV+SOF, according to concomitant RBV use, are shown in Figure 2.", "Two sensitivity analyses were also undertaken: \u2019sensitivity analysis 1\u02b9 treated discontinuations for death and/or AEs as failures but missing data at SVR12 were excluded unless the patient achieved SVR24; \u2019sensitivity analysis 2\u02b9 treated all patients with missing SVR12 data as failures unless they achieved SVR24.", "Overall, observed SVR12 was 99% in the primary analysis irrespective of cirrhosis; in sensitivity analysis 1, 95% of patients with Page 11 of 15 cirrhosis and 98% without achieved SVR12, while in sensitivity analysis 2, SVR12 rates were 90% with and 91% without cirrhosis."], "term": "sensitivity analysis", "termType": "MED", "weight": "b"}, {"score": 0.48882177472114563, "sentences": ["Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a French early access Cohort.", "Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort.", "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).", "In this study of real-world prescription and outcomes, HCV-infected patients initiating DCV+SOF \u00b1RBV were younger, GT-3 infected, and have more clinically advanced liver disease than those initiating other regimens.", "The burden of liver disease in Europe: A review of available epidemiological data.", "Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease."], "term": "liver disease", "termType": "DIS", "weight": "b"}, {"score": 0.48719409108161926, "term": "drug safety", "termType": "MED", "weight": "b"}, {"score": 0.46134594082832336, "term": "controlled study", "termType": "MED", "weight": "b"}, {"links": [{"sublinks": [{"sentences": ["In this paper, the antiviral efficacy and quality-of-life benefits of DCV+SOF(\u00b1RBV) treatment for hepatitis C were assessed in observational data reflecting its routine use in three European countries."], "term": "hepatitis C"}, {"sentences": ["However, in Belgium, reimbursement for any direct-acting HCV antiviral was restricted to those with F3 or F4 liver fibrosis and liver transplant patients, and only DCV and SOF were reimbursed for GT-3 infection."], "term": "hepatitis"}, {"sentences": ["However, in Belgium, reimbursement for any direct-acting HCV antiviral was restricted to those with F3 or F4 liver fibrosis and liver transplant patients, and only DCV and SOF were reimbursed for GT-3 infection."], "term": "graft infection"}, {"sentences": ["However, in Belgium, reimbursement for any direct-acting HCV antiviral was restricted to those with F3 or F4 liver fibrosis and liver transplant patients, and only DCV and SOF were reimbursed for GT-3 infection."], "term": "liver fibrosis"}, {"sentences": ["Hepatitis C may be cured by a course of antiviral drugs, such as the combination of daclatasvir (DCV) and sofosbuvir (SOF) with or without ribavirin (RBV)."], "term": "hepatitis A"}, {"sentences": ["In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir."], "term": "virus hepatitis"}], "term": "adverse drug reaction - disease"}], "score": 0.4530612826347351, "sentences": ["In this paper, the antiviral efficacy and quality-of-life benefits of DCV+SOF(\u00b1RBV) treatment for hepatitis C were assessed in observational data reflecting its routine use in three European countries.", "Antiviral Therapy, 22, 225\u2013236.", "Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6:", "However, in Belgium, reimbursement for any direct-acting HCV antiviral was restricted to those with F3 or F4 liver fibrosis and liver transplant patients, and only DCV and SOF were reimbursed for GT-3 infection.", "Hepatitis C may be cured by a course of antiviral drugs, such as the combination of daclatasvir (DCV) and sofosbuvir (SOF) with or without ribavirin (RBV).", "In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir."], "term": "antivirus agent", "termType": "DRG", "weight": "b"}, {"score": 0.44958075881004333, "sentences": ["Sustained virologic response on DCV+SOF\u00b1RBV (observed) was 96\u2013100% across subgroups of IDU, HIV co-infection, HCV genotype and cirrhosis status.", "In summary, these results confirm the effectiveness and tolerability of DCV+SOF\u00b1RBV for the treatment of HCV in the real-world setting, including subgroups of patients with cirrhosis, HCV/ HIV co-infection, and illicit drug use or OST.", "The non-DCV group contained a higher proportion of patients with HIV co-infection and patients infected with GTs other than The proportions of patients with non-HCV comorbidities were generally similar between groups for most conditions; however, fewer patients with severe hypertension or thyroid disease received DCV.", "The SVR12 rate was also maintained in those with HIV co-infection (97% observed; 94% in sensitivity analyses), which is consistent with the >90% SVR12 rates reported for DCV+SOF\u00b1RBV in real-world early access cohorts of HIV/HCV co-infected patients (Lacombe et al., 2017;", "Subjects: Gastroenterology; Hepatology; Infectious Diseases; ClinicalPharmacology & Therapeutics Keywords: hepatitis C; daclatasvir; sofosbuvir; ribavirin; real-world; quality-of-life; efficacy; safety; cirrhosis; HIV coinfection 2.", "Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.", "Very high rates (\u226596%) of post-treatment sustained virologic response were seen in the primary analysis, irrespective of liver cirrhosis, coinfection with HIV, or illicit drug use.", "Rates of SVR12 remained consistently high across all key subgroups, including cirrhotic status (99% and 100% for compensated and decompensated, respectively), HIV co-infection (97%) and IDUs (99%; Table 3)."], "term": "mixed infection", "termType": "DIS", "weight": "b"}, {"score": 0.41060972213745117, "sentences": ["Treatment regimen and duration was at investigator discretion, in accordance with drug availability, reimbursement and usage guidelines in each participating country.", "However, since SVR12 rates were similar regardless of duration or the inclusion of RBV (Supplementary Figure 1), it appeared that treatment individualization by prescribing physicians was managed effectively."], "term": "treatment duration", "termType": "MED", "weight": "b"}, {"score": 0.38092952966690063, "sentences": ["Notably, the mean age of all patients in the study with severe hypertension (59.7 years) was significantly higher than those without it (50.6 years; p < 0.001), and significantly more of these hypertensive patients were aged \u226565 years (39% versus 12%; p < 0.001).    ", "The non-DCV group contained a higher proportion of patients with HIV co-infection and patients infected with GTs other than The proportions of patients with non-HCV comorbidities were generally similar between groups for most conditions; however, fewer patients with severe hypertension or thyroid disease received DCV.", "By contrast, patients with severe hypertension or GT-1b infection were more likely to have been prescribed a non-DCV regimen (Figure 1).    "], "term": "hypertension", "termType": "DIS", "weight": "b"}, {"score": 0.3668498992919922, "sentences": ["; \u00a7 BMI 17/21; cirrhosis stage (comp. or decomp.) 0/1; FIB-4 44/34; HIV/HCV co-infected 48/45; HCV RNA 15/21; Treatment experience 4/2; ALT 8/11; platelets 11/16; hemoglobin 11/17; abnormal creatinine 39/48; alcohol use 85/54.", "DCV initiation by cirrhosis status and HCV genotype, 3.4.", "ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    ", "Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial."], "term": "Hepatitis C virus genotype 4", "termType": "MED", "weight": "b"}, {"score": 0.3608786463737488, "sentences": ["DCV initiation by cirrhosis status and HCV genotype, 3.4.", "DCV initiation by cirrhosis status and HCV genotype", "Sustained virologic response on DCV+SOF\u00b1RBV (observed) was 96\u2013100% across subgroups of IDU, HIV co-infection, HCV genotype and cirrhosis status.", "DCV, daclatasvir; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR12, sustained virologic response at 12 weeks post-treatment.    ", "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).", "Alloral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:", "ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    ", "Multivariate predictors of DCV treatment included genotype 3 infection (odds ratio 85.9 [95% confidence interval 43.5\u2013170]), age \u226565 years (2.0 [1.2\u20133.3]), and cirrhosis (3.3 [2.0\u20135.3]).", "Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.", "Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials."], "term": "genotype", "termType": "MED", "weight": "b"}, {"score": 0.3464639186859131, "sentences": ["Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic hepatitis C virus (HCV) infection and evaluate effectiveness, safety and quality-of-life (QoL) changes for DCV-based regimens.", "    : ABOUT THE AUTHOR PUBLIC INTEREST STATEMENT Hepatitis C is a chronic, debilitating liver infection estimated by the WHO to kill almost 400,000 people annually.", "Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials.", "Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection."], "term": "chronic hepatitis", "termType": "DIS", "weight": "b"}, {"score": 0.3179677128791809, "sentences": ["However, in Belgium, reimbursement for any direct-acting HCV antiviral was restricted to those with F3 or F4 liver fibrosis and liver transplant patients, and only DCV and SOF were reimbursed for GT-3 infection."], "term": "liver fibrosis", "termType": "DIS", "weight": "b"}, {"score": 0.3169613480567932, "sentences": ["Antiviral Therapy, 22, 225\u2013236.", "In this paper, the antiviral efficacy and quality-of-life benefits of DCV+SOF(\u00b1RBV) treatment for hepatitis C were assessed in observational data reflecting its routine use in three European countries."], "term": "antiviral therapy", "termType": "MED", "weight": "b"}, {"score": 0.3125438690185547, "sentences": ["ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    "], "term": "body mass", "termType": "MED", "weight": "b"}, {"score": 0.3035165071487427, "sentences": ["Cite this article as: Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries : The CMPASS-EU cohort study, Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier & Joerg Petersen, Cogent Medicine (2020), 7: 1727169. ", "In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir.", "Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort.", "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).", "Subjects: Gastroenterology; Hepatology; Infectious Diseases; ClinicalPharmacology & Therapeutics Keywords: hepatitis C; daclatasvir; sofosbuvir; ribavirin; real-world; quality-of-life; efficacy; safety; cirrhosis; HIV coinfection 2.", "The group have authored this manuscript on behalf of the many investigators who carried out this study of real-world hepatitis C treatment in Germany, Belgium and the Netherlands.    ", "In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.", "Prescription and efficacy of daclatasvir and sofosbuvir \u00b1 ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study", "Hepatitis C may be cured by a course of antiviral drugs, such as the combination of daclatasvir (DCV) and sofosbuvir (SOF) with or without ribavirin (RBV).", "Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial.", "Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.", "Effect of voluntary licenses for hepatitis C medicines on access to treatment: A difference-in-differences analysis.", "    : ABOUT THE AUTHOR PUBLIC INTEREST STATEMENT Hepatitis C is a chronic, debilitating liver infection estimated by the WHO to kill almost 400,000 people annually.", "DCV, daclatasvir; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR12, sustained virologic response at 12 weeks post-treatment.    ", "However, in Belgium, reimbursement for any direct-acting HCV antiviral was restricted to those with F3 or F4 liver fibrosis and liver transplant patients, and only DCV and SOF were reimbursed for GT-3 infection.", "Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence.", "Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy:", "These data represent real-world outcomes relevant to clinicians and patients where DCV and SOF are therapeutic options for hepatitis C. \u00a9 2020 The Author(s).", "Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic hepatitis C virus (HCV) infection and evaluate effectiveness, safety and quality-of-life (QoL) changes for DCV-based regimens.", "Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.", "A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.", "Virologic response among hepatitis C (HCV) patients treated in clinical practice [abstract 1084]. Hepatology, 54, 875A. Page 14 of 15 \u00a92020 The Author(s).", "In this paper, the antiviral efficacy and quality-of-life benefits of DCV+SOF(\u00b1RBV) treatment for hepatitis C were assessed in observational data reflecting its routine use in three European countries.", "Progress report on access to hepatitis C treatment:", "Management of hepatitis C virus infection.", "Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic Page 13 of 15 hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials.", "Alloral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:", "ALT, alanine aminotransferase; BMI, body mass index; DCV, daclatasvir; FIB-4, Fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitor; SD, standard deviation; SOF, sofosbuvir.    ", "Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence.", "JAIDS Journal of Acquired Immune Deficiency Syndromes, 75(1), 97\u2013107. doi:10.1097/ Hepatitis C virus infection."], "term": "hepatitis", "termType": "DIS", "weight": "a"}], "timestamp": 1583237376.0, "version": "1.0"}